Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 PS and side effects

From: Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer

Characteristics Treatment group (n = 21) Control group (n = 59)
Grade 1–2 Grade 3 Grade 4 Grade 1–2 Grade 3 Grade 4
Fever 5 (23.8 %) 0 0 13 (22.0 %) 0 0
Anorexia 3 (14.3 %) 0 0 6 (10.2 %) 0 0
Allergy 1 (4.8 %) 0 0 0 0 0
Nausea, vomiting 3 (14.3 %) 0 0 9 (15.3 %) 0 0
Heart function 0 0 0 0 0 0
Liver function 0 0 0 0 0 0
Renal function 0 0 0 0 0 0
Myelosuppression 2 (9.5 %) 0 0 8 (13.6 %) 0 0
Radiation pneumonitis 4 (19.0 %) 3(14.3 %) 0 11 (18.6 %) 9(15.3 %) 0
PS change after TRT 0.48 ± 0.7* 0.9 ± 0.7
  1. *PS change is significantly better than control group (P < 0.05)